Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check6 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedStudy status updated to Completed with 137 participants enrolled and a completion date of 2026-01-28, with the record revision to v3.4.2. The previous funding notice and the 'Active, not recruiting' indicator were removed.SummaryDifference0.7%

- Check41 days agoChange DetectedAdded a site-wide notice about a lapse in government funding, stating the NIH Clinical Center is open and directing users to cc.nih.gov and opm.gov for status updates. Updated the system revision from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check48 days agoChange DetectedThe page now includes a glossary toggle and updated QC-related labels and revision information (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), replacing the previous labels and version (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

- Check55 days agoChange DetectedAdded EU CT registry identifier 2023-503587-17-00 and updated key dates to 2026-01-28, while removing the previous registry identifier 2023-503587-17 and earlier dates.SummaryDifference0.3%

- Check62 days agoChange DetectedThe page now displays revision v3.3.4, replacing the previous revision v3.3.3.SummaryDifference0.0%

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.